{"@context":{"@vocab":"https://schema.org/"},"@type":"ItemList","@id":"https://api.ai-analytics.org/api/v1/fda/warning-letters/check?name=CES%20LLC","name":"CES LLC","_source":{"data_provider":"AI Analytics","data_provider_url":"https://api.ai-analytics.org","license":"https://creativecommons.org/publicdomain/zero/1.0/","primary_source":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters","generated_at":"2026-08-11T21:37:13.855Z"},"count":3,"matches":[{"id":"d0011298e2619025","posted_date":"2026-03-03","letter_issue_date":"2026-02-20","company_name":"Ivim Services LLC dba Ivim","issuing_office":"Center for Drug Evaluation and Research (CDER)","subject":"False & Misleading Claims/Misbranded (Telehealth)","canonical_url":"https://api.ai-analytics.org/fda-warning/d0011298e2619025"},{"id":"78766824a8cb3cb2","posted_date":"2022-01-25","letter_issue_date":"2022-01-18","company_name":"CES LLC","issuing_office":"Center for Drug Evaluation and Research | CDER","subject":"Drug Product/Misbranded","canonical_url":"https://api.ai-analytics.org/fda-warning/78766824a8cb3cb2"},{"id":"2331cfaf31aabf04","posted_date":"2021-04-27","letter_issue_date":"2021-04-08","company_name":"Exela Pharma Sciences LLC","issuing_office":"Office of Pharmaceutical Quality Operations, Division II","subject":"Unapproved New Drug/Compounding/Misbranding","canonical_url":"https://api.ai-analytics.org/fda-warning/2331cfaf31aabf04"}]}